ORIGINAL RESEARCH

Cardiovascular Disease Mortality Among Hispanic Versus Non-Hispanic White Adults in the United States, 1999 to 2018

Safi U. Khan ^(b), MD, MS; Ahmad N. Lone, MD; Siva H. Yedlapati, MD, MPH; Sourbha S. Dani ^(b), MD, MSc; Muhammad Zia Khan ^(b), MD; Karol E. Watson ^(b), MD, PhD; Purvi Parwani, MD; Fatima Rodriguez ^(b), MD, MPH; Miguel Cainzos-Achirica ^(b), MD, MPH, PhD; Erin D. Michos ^(b), MD, MHS

BACKGROUND: Life expectancy has been higher for Hispanic versus non-Hispanic White (NHW) individuals; however, data are limited on cardiovascular disease (CVD) mortality.

METHOD AND RESULTS: Using the Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research death certificate database (1999–2018), we compared age-adjusted mortality rates for total CVD and its subtypes (ischemic heart disease, stroke, heart failure, hypertensive heart disease, other CVD), and average annual percentage changes among Hispanic and NHW adults. The age-adjusted mortality rate per 100 000 was lower for Hispanic than NHW adults for total CVD (186.4 versus 254.6; P<0.001) and its subtypes. Between 1999 and 2018, mortality decline was higher in Hispanic than NHW adults for total CVD (average annual percentage change [AAPC], –2.90 versus –2.41) and ischemic heart disease (AAPC: –4.44 versus –3.82) (P<0.001). In contrast, stroke mortality decline was slower in Hispanic versus NHW adults (AAPC: –2.05 versus –2.60; P<0.05). Stroke mortality increased in Hispanic but stalled in NHW adults since 2011 (AAPC: 0.79 versus –0.09). For ischemic heart disease (AAPC: –0.80 versus –1.85) and stroke (AAPC: –1.32 versus –1.43) mortality decline decelerated more for Hispanic than NHW adults aged <45 years (P<0.05). For heart failure, Hispanic adults aged <45 (3.55 versus 2.16) and 45 to 64 (1.88 versus 1.54) showed greater rise in age-adjusted mortality rate than NHW individuals (P<0.05). Age-adjusted heart failure mortality rate also accelerated in Hispanic versus NHW men (1.00 versus 0.67; P<0.001).

CONCLUSIONS: Disaggregating data by CVD subtype and demographics unmasked heterogeneities in CVD mortality between Hispanic and NHW adults. NHW adults had greater CVD mortality rates and slower decline than Hispanic adults, whereas marked demographic differences in mortality signaled concerning trends among the Hispanic versus NHW population.

Key Words: cardiovascular mortality
epidemiology
Hispanics

Despite medical advancements and public health interventions, cardiovascular disease (CVD) remains the leading cause of death in the United States and worldwide.¹ Furthermore, the rate of decline in CVD mortality has been slowing down.² Recent data have demonstrated that decline in CVD mortality has decelerated since 2011.² Prior studies have shown startling patterns of racial and ethnic disparities in CVD mortality.^{1,3} However, the body of evidence exploring

CVD mortality predominantly has focused on non-Hispanic racial and ethnic subgroups; less is known about CVD death characteristics among Hispanic/ Latino ethnicity individuals—one of the fastest-growing segments of the US population.⁴

According to the US Census Bureau, the Hispanic population is expected to grow by 86% between 2015 and 2050, to a projected 119 million by 2060.^{4,5} Hispanic individuals have traditionally faced socioeconomic

Correspondence to: Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, Division of Cardiology, Johns Hopkins University School of Medicine, Blalock 524-B, 600 N. Wolfe Street, Baltimore, MD 21287. E-mail: edonnell@jhmi.edu

Supplemental Material for this article is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.121.022857

For Sources of Funding and Disclosures, see page 11.

^{© 2022} The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: www.ahajournals.org/journal/jaha

CLINICAL PERSPECTIVE

What Is New?

- Cardiovascular disease (CVD) mortality trends varied among Hispanic and Non-Hispanic White (NHW) adults in the United States.
- NHW adults had greater CVD mortality and slower decline than Hispanic adults. Whereas decline in stroke mortality was slower for Hispanic than NHW adults, heart failure mortality accelerated in Hispanic versus NHW men.

What Are the Clinical Implications?

- Unraveling data by CVD subtype and demographics exposed concerning trends in CVD mortality between Hispanic and NHW adults.
- The reasons for the deceleration in CVD mortality decline among NHW population and diverse trends in Hispanic population need to be explored at a deeper level.

Nonstandard Abbreviations and Acronyms

AAPC average annual percentage rate changeIHD ischemic heart diseaseNHW non-Hispanic White

deprivation and carry a disproportionally higher burden of CVD.^{4,5} Despite this, preliminary data have shown a lower mortality for Hispanic than non-Hispanic White (NHW) individuals—the so-called Hispanic paradox, by which Hispanic adults would have cardiovascular protective features, such as strong family and social support, genetics, and dietary habits, that would counteract the effect of adverse social determinants of health and attenuate that of certain prevalent CVD risk factors⁶⁻⁸

However, the scientific literature is inconsistent with regard to the Hispanic paradox, with some studies supporting the phenomenon⁸ while others have opposed its existence,^{9,10} showing that Hispanic adults had a similar or even greater mortality than NHW individuals. Whether the Hispanic mortality paradox still exists and whether this is consistent across CVD subtypes and demographic characteristics remain uncertain. To shed light on this matter, we used national CVD mortality data and compared CVD mortality trends in Hispanic with NHW individuals, stratified by age, sex, CVD subtypes, and urbanicity between 1999 and 2018.

METHODS

The Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research used in this project is publicly available and are easily replicable from the methods described in the article.

Data Source

We reviewed the Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research database, composed of death certificates in the United States filed in the 50 states and District of Columbia.¹¹ We identified race and ethnicity on death certificates as NHW adults, non-Hispanic Black adults, and Hispanic adults. We exclusively compared Hispanic adults with NHW adults to provide standard assessment of mortality rates among Hispanic population in relation to a majority NHW population (*control group*). We excluded non-Hispanic Black individuals from the analysis because the latter are also treated as minority population and would not provide a fair assessment of Hispanic mortality estimates.

Ethnicity and race were reported on the death certificate as per the standards set forth by the Office of Management and Budget.¹² Ethnicity and race information of the decedent is reported by the funeral director as provided by an informant, often the surviving next of kin, or, in the absence of an informant, based on observation. Ethnicity and race information from the census is self-described.¹³ Race and Hispanic ethnicity can be inconsistent between these 2 databases; therefore, a degree of bias in mortality rates cannot be ignored. Some death certificates did not mention Hispanic origin and were coded as "not stated." We excluded those death certificates from the analysis.

We identified the natural cause of death according to the World Health Organization statement,14 attributed to CVD and subtypes among adults (aged \geq 18 years). We identified mortality information using the International Classification of Diseases, Tenth Revision (ICD-10) codes with the underlying cause of total CVD, which comprised subtypes classified as ischemic heart disease (IHD; ICD-10: I20-I25), heart failure (HF, I50), stroke (I60-I69), hypertensive heart disease (I11) and other CVDs (pulmonary heart disease [126-128], valvular heart disease [I34-I38], arrhythmia [I47-I49], acute rheumatic fever and chronic rheumatic heart disease [100-109], pericardial diseases [130-133], acute myocarditis [I40-I46], and complications of the ill-defined description of heart disease [I51]).^{15,16} We grouped the later as "Other CVDs" because of low death counts. The population estimates used for this analysis are Census Bureau estimates of US national, state, and county resident populations (Data S1).13

This study did not require institutional review board approval since we analyzed government-issued publicly available databases without individually identifiable information.

Data Extraction

We abstracted the number of cause-specific CVD deaths and population sizes for age, sex, and 2013 county-level urban-rural classification for Hispanic and NHW adults from 1999 to 2018. We collapsed urban counties into the large metro (large central metro, large fringe metro) and medium-small metros, whereas rural counties were composed of micropolitan and noncore (nonmetropolitan counties that did not qualify as micropolitan).¹⁷

Statistical Analysis

We estimated age-adjusted (to the 2000 US standard population)¹⁸ mortality rates for each year per 100 000 population within the county, across the counties within a particular state, and across the entire United States. Using this approach, we suppressed rates for data demonstrating 0 to 9 deaths along with the corresponding denominator population when the population showed <10 persons. For deaths <20, rates were considered unreliable and were not computed during the estimation of age-adjusted rates. Since we aggregated death rates across counties, all counties were included regardless of population size and death counts.

We analyzed temporal trends by fitting log-linear regression models using the Joinpoint Regression Program version 4.7.0.0 (National Cancer Institute). We calculated average annual percentage rate change (AAPC) with 95% CIs in age-adjusted mortality rates for all analyses from 1999 to 2018, further divided into 1999 to 2011 and 2011 to 2018, weighted to account for differences in the number of inflection points.^{15,19} We identified the year 2011 as the inflection point in total CVD mortality trends, consistent with prior studies reporting national CVD mortality trends.^{2,15} Slopes were considered increasing or decreasing if the estimated slope differed significantly from 0.19,20 We applied a specific procedure- comparability test to determine whether 2 regression mean functions are parallel because of different intercepts (test of parallelism).²¹ Analyses were stratified by age (<45 years, 45-64 years, and \geq 65 years), as well as by sex and urbanicity. For all analyses, statistical significance was set at 5%. For additional details please see the Supplementary Methods section.

RESULTS

Between 1999 and 2018, a total of 834 532 total CVD deaths occurred in Hispanic people (955 395 222

person-years), and 14 288 611 deaths in NHW adults (4 193 681 875 person-years). Overall, IHD was the leading cause of CVD death. Hispanic adults had a lower age-adjusted mortality rate (186.4; 95% Cl, 186.0–186.8 per 100 000) than NHW adults (254.6; 95% Cl, 254.5–254.7 per 100 000) for total CVD (*P*<0.001), which was consistent for CVD subtypes.

Trends in CVD Mortality

Between 1999 and 2018, mortality decline was higher in Hispanic than NHW adults for total CVD (AAPC, -2.90 versus -2.41) and IHD (AAPC, -4.44 versus -3.82), but not for stroke (AAPC, -2.05 versus -2.60) (P test for parallelism < 0.001 for all; Table 1). For hypertensive heart disease, mortality escalated in NHW versus Hispanic patients (AAPC, 3.07 versus 1.87; P<0.001). Between 1999 and 2011, Hispanic adults exhibited a decline in mortality at an AAPC of -3.88 (95% CI, -4.26 to -3.49) for total CVD, -5.20 (95% CI, -6.57 to -3.80) for IHD, and -3.67 (95% CI, -3.95 to -3.39) for stroke, but stagnation for hypertensive heart disease (1.45; 95% Cl, -0.51 to 3.46) (Figure 1; Table S1). Similar trends were noted in NHW individuals, except mortality increased because of hypertensive heart disease at AAPC of 1.93 (95% CI, 1.58-2.28). Examining time periods, the mortality slowed down for both Hispanic and NHW adults for total CVD (AAPC, -0.86 and -0.63, respectively) and IHD (AAPC, -3.07 and -2.47, respectively), and increased for hypertensive heart disease (AAPC, 2.60 and 5.04, respectively) between 2011 and 2018. The AAPC showed that mortality attributable to stroke (0.79; 95% CI, 0.03-1.56) has increased in Hispanic adults but has stalled (-0.09; 95% CI, -0.51 to 0.33]) in NHW patients since 2011.

Trends in CVD Mortality by Age

Between 1999 and 2018, decline in AAPC in ageadjusted mortality rates was greater in Hispanic than NHW individuals for total CVD across all age groups (P<0.05 for all; Table 2). Conversely, for IHD (AAPC, -0.80 versus -1.85) and stroke (AAPC, -1.32 versus -1.43) mortality decline slowed down more for Hispanic than NHW adults aged <45 years (P<0.05). For both the study groups, mortality attributable to HF increased for ages <45 years and 45 to 64 years, and across all age groups for hypertensive heart disease. However, AAPC for Hispanic adults aged <45 years (3.55 versus 2.16) and 45 to 64 years (1.88 versus 1.54) showed a greater rise in HF mortality than for NHW patients (P<0.05). Whereas NHW adults showed a greater rise in mortality attributable to hypertensive heart disease than Hispanic adults across all age groups (P<0.001).

After an initial decline, AAPC in total CVD mortality increased in Hispanic patients aged <45 years (1.14, 95% Cl, 0.57–1.71), stalled in those aged 45 to 64 years

Table 1. Tre	ands in Cardiovasc	ular Disease Mort	ality Between His	Table 1. Trends in Cardiovascular Disease Mortality Between Hispanic and Non-Hispanic White adults in the United States, 1999 to 2018	anic White adults i	in the United Sta	tes, 1999 to 2018		
	Hispanic adults				Non-Hispanic White adults	adults			
	Age-adjusted mortality rate (95% CI)	ality rate (95% CI)		AAPC (95% CI)	Age-adjusted mortality rate (95% CI)	lity rate (95% CI)		AAPC (95% CI)	Test for parallelism
	1999 (n=33 665)	2011 (n=40 794)	2018 (n=56 217)	(1999–2018)	1999 (n=744 329)	2011 (n=581 619)	2018 (n=616 522)	(1999–2018)	P value
Total cardiovascular disease		267.7 (264.7–270.7) 166.5 (164.8–168.2)		156.7 (155.4–158.1) –2.90 (–3.21 to –2.58)	322.7 (322.0–323.5)	211.5 (210.9–212.0)	201.4 (200.9–201.9)	211.5 (210.9–212.0) 201.4 (200.9–201.9) –2.41 (–2.76 to –2.05)	<0.001
Ischemic heart disease	lschemic heart 162.2 (159.8–164.5) disease	84.2 (83.0–85.4)	69.1 (68.2–70.0)	-4.44 (-4.85 to -4.02) 194.3 (193.7-194.9)	194.3 (193.7–194.9)	111.1 (110.7–111.5)	93.5 (93.1–93.8)	-3.82 (-4.12 to -3.52)	<0.001
Heart failure	11.1 (10.5–11.8)	10.1 (9.6–10.5)	11.8 (11.5–12.2)	0.55 (-0.44 to 1.55)	20.6 (20.4–20.8)	17.5 (17.3–17.7)	21.7 (21.6–21.9)	0.33 (-0.28 to 0.94)	0.16
Hypertensive heart disease	6.9 (6.5–7.4)	7.8 (7.4–8.1)	9.7 (9.4–10.0)	1.87 (0.37–3.38)	6.8 (6.7–6.9)	8.5 (8.4–8.6)	12.1 (11.9–12.2)	3.07 (2.55 to 3.59)	<0.001
Stroke	46.6 (45.3-47.8)	30.7 (30.0–31.4)	32.0 (31.4–32.6)	-2.05 (-2.39 to -1.70)	59.8 (59.5–60.1)	36.7 (36.5–36.9)	35.9 (35.7–36.1)	-2.60 (-3.10 to -2.11)	<0.001
Other cardiovascular diseases	23.4 (22.5–24.2)	20.3 (19.7–20.9)	19.3 (18.9–19.8)	-0.77 (-1.11 to -0.44)	41.2 (40.9–41.4)	37.7 (37.5–37.9)	38.3 (38.1–39.1)	-0.37 (-1.07 to 0.33)	<0.001
AAPC indicat	AAPC indicates average annual percent change.	sent change.							

(-0.26; 95% Cl, -0.70 to 0.19) and slowed down among those ≥65 years (-1.03 95% CI, -1.47 to -0.59]) since 2011. AAPC in total CVD mortality decreased in NHW adults aged <45 years (-0.46; 95% Cl, -0.90 to -0.02), increased in those aged 45 to 64 years (0.29; 95% CI, 0.10-0.48), and slowed down in those aged ≥65 years (-0.80; 95% Cl, -1.04 to -0.55) since 2011 (Figure 2; Table S2). For IHD, mortality decreased for adults aged 45 to 64 years and ≥65 years between 1999 and 2011, followed by a deceleration since 2011 for both Hispanic and NHW patients. After an initial decrease, stroke mortality flattened in Hispanic adults aged <45 years (AAPC, -0.53; 95% Cl, -2.35 to 1.32) and 45 to 64 years (0.48; 95% Cl, -2.45 to 1.53) and increased among those ≥65 years (1.06; 95% CI, 0.21-1.91) between 2011 and 2018. Conversely, among NHW patients, stroke mortality increased in those aged<45 years (0.31; 95% Cl, 1.77-2.44) and 45 to 64 years (0.59; 95% CI, 0.24-0.94) and stalled in those aged ≥65 years (-0.16; 95% CI, -0.59 to 0.26) since 2011

Trends in CVD Mortality by Sex

Between 1999 and 2018, AAPCs in age-adjusted mortality rates were greater in Hispanic than NHW adults for total CVD and IHD, except stroke mortality decreased at a slower rate for both sexes (P<0.001; Table 3). Similarly, HF mortality showed an acceleration in Hispanic men versus NHW men (AAPC, 1.00 versus 0.67; P<0.001). For hypertensive heart disease, the rise in mortality was higher in NHW versus Hispanic adults for both sexes (P < 0.001).

Between 1999 and 2011, for both study groups, the mortality decreased for total CVD and IHD, followed by slowing down for both sexes since 2011 (Figure 3; Table S3). However, after an initial decline in stroke mortality for both sexes, mortality has stalled in Hispanic women (AAPC, 0.76; 95% Cl, -0.01 to 1.53) and increased in men (0.92; 95% Cl, 0.27-1.58), but stalled in both NHW sexes between 2011 and 2018.

Trends in CVD Mortality by Urbanicity

Between 1999 and 2018, decline in AAPCs in ageadjusted mortality rates were greater in Hispanic people than NHW adults for total CVD and IHD across counties (Table 4). This pattern was not consistent for stroke, where mortality decreased at a slower rate for large (AAPC, -1.71 versus -2.53; P<0.001) and medium/small metro (-2.64 versus -2.70; P<0.001) counties but declined at a greater pace in rural counties (-3.76 versus -2.70; P<0.001) among Hispanic versus NHW adults (Table 4). Similarly, for HF, mortality increased at a higher pace in Hispanic residents of large metros versus the NHW population (1.37 versus 1.08; P<0.001).




Figure 1. Trends of age-adjusted mortality rates attributable to total cardiovascular disease and its components in Hispanic and Non-Hispanic White individuals in the United States, 1999 to 2018. AAMR indicates age-adjusted mortality rate; and NH, non-Hispanic.

Between 1999 and 2011, AAPC for total CVD decreased in large metro (-3.80 versus -3.72), mediumsmall metro (-3.40 versus -3.42), and rural counties (-4.19 versus -2.98), while it has slowed down in all 3 county subtypes for both study groups since 2011 (Table S4). While this pattern was consistent for IHD, for stroke, AAPCs in age-adjusted stroke mortality rates have increased at a higher pace (1.70 versus 0.68) in large metro but reduced at a greater rate in rural counties (-1.67 versus -1.27) in Hispanic versus NHW residents.

DISCUSSION

In this analysis, we document diverging trends in CVD mortality between Hispanic and NHW adults in the United States during the past 2 decades. Between 1999 and 2018, mortality decline was higher in Hispanic than NHW adults for total CVD and IHD. However, stroke mortality decline was greater in NHW than Hispanic adults. For hypertensive heart disease, mortality escalated in NHW versus Hispanic individuals. Analyzing demographic characteristics unmasked critical trends for both study groups. For instance, CVD mortality increased in Hispanic adults aged <45 years after 2011, while it decreased in the same age group in NHW adults. Compared with NHW adults, Hispanic

adults aged <45 years exhibited a slow decline in stroke mortality because of flattening after 2011, while among Hispanic people aged ≥65 years, mortality has accelerated since 2011. There were also sex differences in the deceleration of the reduction of stroke mortality in Hispanic versus NHW adults because of stalling in Hispanic women and rise in Hispanic men since 2011. HF mortality has increased in Hispanic adults aged <45 years and 45 to 64 years and Hispanic men compared with the NHW group.

Overall, NHW adults had higher CVD mortality than Hispanic individuals. In certain scenarios, such as hypertensive heart disease, mortality increased compared with the Hispanic population. After decades of increases in life expectancy, a concerning shift representing stagnant CVD mortality statistics in the United States were observed in 2011.¹⁹ CVD mortality rates in many high-income countries, after falling by up to 80% over the past 4 decades, are now either declining at progressively slower rates or even showing concerning acceleration.²² The heart disease death rate for NHW men declined 19% between 1999 (226.6 per 100 000) and 2009 (184.2 per 100 000) and then increased 4% between 2009 and 2017 (192.3 per 100 000).23 This concerning shift has been attributed to increasing cardiometabolic risk factors, especially among adults aged 35 to 64 years, including obesity and diabetes

		Hispanic adults				Non-Hispanic White adults	ults			
169 2011 2016 1696 2011 1696 2011 2016		Age-adjusted mo	ortality rate (95% C	(AAPC (95% CI)	Age-adjusted mortality	rate (95% Cl)		AAPC (95% CI)	Test for parallelism
INTROPOSITION INTROPOSITION <th< th=""><th></th><th>1999</th><th>2011</th><th>2018</th><th>(1999–2018)</th><th>1999</th><th>2011</th><th>2018</th><th>(1999–2018)</th><th>P value</th></th<>		1999	2011	2018	(1999–2018)	1999	2011	2018	(1999–2018)	P value
V 12 (7.5-8.2) 6.5 (8.2-6.8) 8.7 (6.4-7.0) -0.67 (-1.03 (-1.7.6) 10.5 (1(6.2-103))	Total cardiov	/ascular disease	_							
N N	<45 y	7.8 (7.5–8.2)	6.5 (6.2–6.8)	6.7 (6.4–7.0)	-0.62 (-1.22 to -0.01)	10.7 (10.6–10.9)	10.1 (9.9–10.3)	9.5 (9.3–9.7)	-0.47 (-0.88 to -0.06)	0.01
V 182.47 111.7 1006.0 -2.06 (-3.06 to -2.53) 128.37 (2186.4-2180.0) 126.6 (-3.06 to -2.74) 26.6 (-3.06 to -2.74) ICINEL-IGENTS (10801124.4) (1080.0-1124.4) (1080.0-1124.4) (1080.0-1124.4) 26.6 (-3.06 to -2.53) 218.1 (-1.16) -1.86 (-2.190 to -1.51) 2.86 (-3.06 to -2.90) 17.1 (1161.118.1) 80.4 (79.7 -81.1) 75.3 (74.6 -76.0) 2.29 (-2.410 to -1.51) 2.20 (-2.410 to -1.51) 2.22 (-2.410 to -1	45–64 y	144.2 (140.7–147.8)	98.0 (96.0–100.1)	96.4 (94.7–98.2)	-2.07 (-2.30 to -1.84)	173.3 (172.1–174.5)	133.5 (132.6–134.4)	136.2 (135.2–137.1)	-1.28 (-1.47 to -1.10)	<0.001
No. No. <td>≥65 y</td> <td>1824.7 (1801.9–1847.5)</td> <td>1111.7 (1099.0–1124.4)</td> <td>1036.0 (1026.0–1046.0)</td> <td>-2.95 (-3.36 to -2.53)</td> <td>2193.7 (2188.4–2199.0)</td> <td>1386.9 (1383.0–1390.8)</td> <td>1305.4 (1301.8–1308.9)</td> <td>-2.65 (-3.04 to -2.27)</td> <td><0.001</td>	≥65 y	1824.7 (1801.9–1847.5)	1111.7 (1099.0–1124.4)	1036.0 (1026.0–1046.0)	-2.95 (-3.36 to -2.53)	2193.7 (2188.4–2199.0)	1386.9 (1383.0–1390.8)	1305.4 (1301.8–1308.9)	-2.65 (-3.04 to -2.27)	<0.001
V 22,20-24) 18 (16-13) 18 (17-14) 000 (-178 to 018) 49 (48-60) 42 (41-43) 33 (32-35) -168 (-218 to -156) V 86.3855-89.0 488 (483-51.3) 46.0 (443-472) -325 (-356 to -290) 117 (116, -1181) 160.4 (737 - 211) -2.39 (-2.446 to -4.06) V 1102-11 5601-573 46.0 (443-472) -502 (-538 to -471) 1306.4 (1302 - 2130.05) 716 (773 - 718.05) 233 (54.36 - 553) -4.36 (140 - 4.06)	Ischemic hea	art disease								
(1) (1) <td><45 y</td> <td>2.2 (2.0–2.4)</td> <td>1.8 (1.6–1.9)</td> <td>1.8 (1.7–1.9)</td> <td>-0.80 (-1.78 to 0.18)</td> <td>4.9 (4.8–5.0)</td> <td>4.2 (4.1–4.3)</td> <td>3.3 (3.2–3.5)</td> <td>-1.85 (-2.19 to -1.51)</td> <td>0.02</td>	<45 y	2.2 (2.0–2.4)	1.8 (1.6–1.9)	1.8 (1.7–1.9)	-0.80 (-1.78 to 0.18)	4.9 (4.8–5.0)	4.2 (4.1–4.3)	3.3 (3.2–3.5)	-1.85 (-2.19 to -1.51)	0.02
V 1120-1 680-2 456.7 456.4 45	45–64 y	86.3 (83.5-89.0)	49.8 (48.3–51.3)	46.0 (44.8–47.2)	-3.23 (-3.55 to -2.90)	117.1 (116.1–118.1)	80.4 (79.7–81.1)	75.3 (74.6–76.0)	-2.29 (-2.44 to -2.15)	<0.001
eiller iller iller </td <td>≥65 y</td> <td>1120.1 (1102.2–1138.0)</td> <td>569.2 (560.1–578.3)</td> <td>456.7 (450.0–463.3)</td> <td>-5.02 (-5.33 to -4.71)</td> <td>1306.4 (1302.2–1310.5)</td> <td>716 (713.2–718.8)</td> <td>590.3 (587.9–592.7)</td> <td>-4.36 (-4.66 to -4.06)</td> <td><0.001</td>	≥65 y	1120.1 (1102.2–1138.0)	569.2 (560.1–578.3)	456.7 (450.0–463.3)	-5.02 (-5.33 to -4.71)	1306.4 (1302.2–1310.5)	716 (713.2–718.8)	590.3 (587.9–592.7)	-4.36 (-4.66 to -4.06)	<0.001
y $0.1(0.1-0.3)$ $0.2(0.1-0.3)$ $3.5(1.59-6.56)$ $0.2(0.1-0.3)$ $0.2(0.1-0.3)$ $0.2(0.1-0.3)$ $2.1(6.03-3.96)$ $4y$ $2.7(2-3.2)$ $2.7(2-3.2)$ $2.7(2-3.2)$ $3.7(3.3-4.0)$ $188(0.49-3.28)$ $4.2(4.0-4.4)$ $4.0(3.8-4.1)$ $6.0(5.8-6.1)$ $154(0.91-2.18)$ y $8.0(77.6-77.3)$ $8.0(831-8.8)$ $0.33(-0.43)$ $1.84.6(153.2-156.0)$ $130.4(129.2-131.6)$ $160.0(158.8-161.3)$ $0.2(6-6.7)$ $154(0.91-2.18)$ $srs(r)$ $rot(r)$ $rot(r)$ $2.7(12-3.2)$ $2.8(1,7-0.9)$ $2.37(10.0-3.65)$ $0.33(-0.43)$ $150.4(13-5.65)$ $0.2(6,1-6.7)$ y $0.4(0.3-0.5)$ $0.5(0.4-0.6)$ $0.8(0.7-0.9)$ $2.79(1.90-3.65)$ $0.4(0.3-0.5)$ $0.2(0.1-0.2)$ $0.2(0.1-0.2)$ y $0.4(0.3-0.5)$ $0.5(0.4-0.6)$ $0.8(0.7-0.9)$ $2.79(1.90-3.65)$ $0.4(0.3-0.5)$ $0.2(0.1-0.2)$ $1.28(1.9-6.57)$ y $0.4(0.3-0.5)$ $0.5(0.4-0.6)$ $0.8(0.7-0.9)$ $2.78(1.9-3.65)$ $0.4(0.3-0.5)$ $0.2(0.1-0.2)$ y $0.4(0.3-0.5)$ $0.5(0.4-0.6)$ $0.8(0.7-0.9)$ $1.2(1.7-1.2)$ $1.2(1.7-1.2)$ $5.06(4.18-5.65)$ y $1.2(1.6-1.9)$ $1.2(1.7-1.6)$ $1.2(1.7-1.5)$ $1.2(1.7-1.2)$ $1.2(1.7-3.22)$ y $1.2(1.6-7.6)$ $1.2(1.7-1.6)$ $1.2(1.7-1.6)$ $1.2(1.7-1.2)$ $1.2(1.7-1.2)$ y $1.2(1.6-7.6)$ $1.2(1.7-1.6)$ $1.2(1.7-1.6)$ $1.2(1.7-1.2)$ $1.2(1.7-1.2)$ y $1.2(1.6-7.6)$ $1.2(1.6-7.6)$ $1.2(1.6-7.6)$ $1.2($	Heart failure									
44 $2.7(23.2)$ $2.7(2.4.3.1)$ $3.7(34.0)$ $188(0.49-3.28)$ $12.8(0.49-3.28)$ $12.8(0.49-3.28)$ $12.8(0.49-3.28)$ $12.8(0.49-3.28)$ $12.8(0.49-3.28)$ $12.8(0.49-3.28)$ $12.8(0.41-5)$ $12.8(0.41-5)$ $12.8(0.168.8-161)$ $15.4(0.91-2.18)$ arms remark rowspan="4">arms rowspan="4">arms rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4">rowspan="4" $12.8(1.0-5.16)$ $12.8(1.0-7.13)$ $12.8(1.0-3.16)$ $12.8(1.0-3.64)$ $12.8(1.0-3.64)$ $12.8(1.0-3.64)$ $12.8(1.0-3.64)$ $12.8(1.0-3.64)$ $12.8(1.0-3.64)$ $12.8(1.0-3.64)$ $12.8(1.0-3.64)$ $12.8(1.0-3.64)$ $12.8(1.0-3.65)$ $12.8(1.0-3.65)$ $12.8(1.0-1.25)$ $12.8(1.0-5.65)$ $12.8(1.0-5.76)$	<45 y	0.1 (0.1–0.3)	0.2 (0.1–0.3)	0.2 (0.1–0.3)	3.55 (1.59–5.55)	0.2 (0.1–0.3)	0.2 (0.1–0.3)	0.3 (0.2–0.4)	2.16 (0.36–3.98)	0.01
V 82.6 (77.6 - 87.5) 74.0 (70.7 - 77.3) 86.0 (83.1 - 86.9) 0.33 (-0.43 to 1.09) 154.6 (153.2 - 156.0) 130.4 (129.2 - 131.6) 160.0 (158.6 - 161.3) 0.25 (-0.33 to 0.84) Amminimum 0.4 (0.3 - 0.5) 0.5 (0.4 - 0.6) 0.8 (0.7 - 0.9) 2.79 (1.90 - 369) 0.4 (0.3 - 0.5) 11 (1.0 - 1.2) 5.6 (64.18 - 5.95) 5.18 (450 - 5.76) A 0.4 (0.3 - 0.5) 0.5 (0.4 - 0.6) 0.8 (0.7 - 0.9) 2.70 (0.7 - 3.46) 4.9 (4.7 - 5.1) 12 (1.1 - 1.2) 5.18 (450 - 5.76) Y 3.3 (39.8 - 46.5) 1.8 (1.7 - 8.3) 2.07 (0.7 - 3.46) 4.3 (4.7 - 5.1) 12 (1.1 - 1.2) 5.18 (4.60 - 5.76) Y 1.7 (1.6 - 1.9) 1.4 (4.2 - 15) 1.8 (1.0 - 1.7) 1.3 (1.2 - 1.3) 1.5 (1.4 - 1.6) 1.2 (1.1 - 1.2) 1.43 (1.0 - 1.2) Y 1.7 (1.6 - 1.9) 1.4 (1.2 - 1.5) 1.8 (10.1 - 3.2) 1.3 (1.4 - 16) 1.5 (1.4 - 16.0) 1.43 (1.6 - 2.6) 1.43 (1.6 - 2.6) 1.43 (1.6 - 2.6) 1.43 (1.6 - 2.6) 1.43 (1.6 - 2.6) 1.43 (1.6 - 2.6) 1.43 (1.6 - 2.6) 1.43 (1.6 - 2.6) 1.43 (1.6 - 2.6) 1.43 (1.6 - 2.6) 1.43 (1.6 - 2.6) 1.43 (1.6 - 2.6)	45–64 y	2.7 (2.2–3.2)	2.7 (2.4–3.1)	3.7 (3.3–4.0)	1.88 (0.49–3.28)	4.2 (4.0-4.4)	4.0 (3.8–4.1)	6.0 (5.8–6.1)	1.54 (0.91–2.18)	<0.001
matrix Not the next disease Y 0.4 (0.3-0.5) 0.5 (0.4-0.6) 0.8 (0.7-0.9) 2.79 (1.90-3.6) 0.4 (0.3-0.5) 0.9 (0.8-1.0) 1.1 (1.0-1.2) 5.06 (4.18-5.95) 5.06 (4.18-5.95) 4Y 5.5 (4.8-6.2) 7.1 (6.5-7.6) 0.8 (0.7-0.3.45) 0.4 (0.3-0.5) 0.9 (0.7-0.3.65) 0.4 (0.3-0.5) 5.06 (4.18-5.95) 5.18 (4.60-5.76) 5.11.38 (6-1.100) 1.12 (1.1-1.3) 1.12 (1.1-1.3) 1.13 (1.2.1-1.3) 1.13	≥65 y	82.6 (77.6-87.5)	74.0 (70.7–77.3)	86.0 (83.1-88.9)	0.33 (-0.43 to 1.09)	154.6 (153.2–156.0)	130.4 (129.2–131.6)	160.0 (158.8–161.3)	0.25 (-0.33 to 0.84)	0.24
V 0.4 (0.3-0.5) 0.5 (0.4-0.6) 0.8 (0.7-0.9) 2.70 (1.0-3.46) 0.4 (0.3-0.5) 0.9 (0.8-1.0) 11 (1.0-1.2) 5.06 (4.18-5.6) 5.18 (4.60-5.76) 44 5.5 (4.8-6.2) 7.1 (6.5-7.6) 7.8 (7.3-8.3) 2.07 (0.70-3.46) 4.9 (4.7-5.1) 9.2 (9.0-9.5) 12.2 (119-12.5) 5.18 (4.60-5.76) 5.18 (4.60-5.76) y 43.3 (39.8-46.9) 46.4 (43.8-49.0) 59.3 (56.9-61.7) 1.81 (0.17-3.47) 43.3 (42.5-44.0) 46.5 (47.6-0.3) 2.46 (1.71-3.22) 2.46 (1.71-3.22) y 1.7 (1.6-1.9) 1.4 (1.2-1.5) 1.3 (1.2-1.5) 1.81 (0.17-3.81) 43.3 (42.5-44.0) 46.5 (45.8-47.2) 68.5 (67.7-69.3) 2.46 (1.71-3.22) y 2.43 (1.71-8.9) 1.81 (0.17-8.1) 1.81 (0.17-8.1) 1.81 (0.17-8.1) 1.81 (0.17-8.1) 1.43 (-1.86 to -1.00) y 2.43 (2.9-25.8) 18.0 (17.1-18.9) 1.8.8 (16.0-16.7) 1.8.8 (1-0.16.7) 1.43 (-1.86 to -1.00) y 2.43 (2.9-25.8) 18.0 (17.1-18.9) 1.8.8 (16.0-16.7) 1.2.8 (1-1.6.1) 1.1.3 (1-2.1.2) 1.43 (-1.86 to -1.00) y 2.43 (2.92 - 2.5.8) 18.0	Hypertensiv	e heart disease								
44 5.5(4.8-6.2) 7.1(5.5-7.6) 7.8(7.3-8.3) 2.07(0.70-3.46) 4.9(4.7-5.1) 2.2(9,0-9.5) 1.2.2(119-12.5) 5.18(4.60-5.76) 7 43.3(39.3-46.9) 46.4(43.3-49.0) 59.3(56.9-61.7) 1.81(0.17-3.47) 43.3(42.5-44.0) 46.5(45.8-47.2) 68.5(67.7-69.3) 2.46(1.71-3.22) 7 1.7(1-6-1.9) 1.4(1.2-1.5) 1.3(1.2-1.5) 1.3(1.2-1.5) 1.3(1.2-1.5) 1.3(1.2-1.5) 2.46(1.71-3.22) 94 24.3 (22.9-25.8) 18.0 (17.1-18.9) 1.3(1.2-1.5) 1.3.2(-3.70-0.93) 15.7(15.4-16.0) 16.3(16.0-16.7) 1.43(-1.86 to -1.00) 94 24.3 (22.9-25.8) 18.0 (17.1-18.9) 1.3(1.2-1.5) 2.02(-3.06 to -0.97) 19.9 (19.5-20.3) 15.7(15.4-16.0) 16.3(16.0-16.7) 1.43(-1.86 to -1.00) 94 24.3 (22.9-25.8) 18.0 (17.1-18.9) 16.3 (16.0-16.7) 16.3 (16.0-16.7) 1.43 (-1.86 to -1.00) 94 24.3 (22.9-25.8) 18.0 (17.1-18.9) 16.3 (16.0-16.7) 16.3 (16.0-16.7) 1.43 (-1.86 to -1.00) 91 16.9 (21.23-25.4) 16.3 (16.0-16.7) 16.3 (16.0-16.7) 16.3 (16.0-16.7) 1.43 (-1	<45 y	0.4 (0.3-0.5)	0.5 (0.4–0.6)	0.8 (0.7–0.9)	2.79 (1.90–3.69)	0.4 (0.3-0.5)	0.9 (0.8–1.0)	1.1 (1.0–1.2)	5.06 (4.18–5.95)	<0.001
V 43.3 (39.8-46.9) 46.4 (4.3.8-49.0) 59.3 (56.9-61.7) 18.1 (0.17-3.47) 43.3 (42.5-44.0) 46.5 (45.8-47.2) 68.5 (67.7-69.3) 2.46 (1.71-3.22) X 1.7 (1.6-1.9) 1.4 (1.2-1.5) 1.3 (1.2-1.5) -1.32 (-1.71 to -0.93) 1.5 (1.4-1.6) 1.2 (1.1-1.3) -1.43 (-1.86 to -1.00) X4 24.3 (22.9-25.8) 18.0 (17.1-18.9) 16.8 (16.0-17.5) -2.02 (-3.06 to -0.97) 19.9 (195-20.3) 15.7 (15.4-16.0) 16.3 (16.0-16.7) -1.08 (-1.38 to -0.77) X5 24.3 (27.3-256.4) 16.3 (16.0-16.7) 2.02 (-3.06 to -0.97) 19.9 (195-20.3) 15.7 (15.4-16.0) 16.3 (16.0-16.7) -1.08 (-1.38 to -0.77) X5 24.3 (27.3-256.4) 16.3 (10.3-6.5) 2.04 (-2.43 to -1.66) 430.3 (42.7) 266.5 (25.48-258.2) 248.9 (247.3-256.4) -2.82 (-3.47 to -2.16) X5 204.3 (27.9 - 20.3) 19.3 (12.7 (12.4-16.0) 16.7 (11.2 (1.3) -1.08 (-1.38 to -0.77) X5 204.3 (27.9 - 21.6) 430.3 (42.7) (42.8 (28.8) 248.9 (247.3 - 250.4) -2.82 (-3.47 to -2.16) X5 204.3 (20.8 - 20.8) 20.4 (-2.43 to -1.66) 430.3 (42.79 - 42.2) 248.9 (247.3 - 25	45–64 y	5.5 (4.8–6.2)	7.1 (6.5–7.6)	7.8 (7.3–8.3)	2.07 (0.70–3.46)	4.9 (4.7–5.1)	9.2 (9.0–9.5)	12.2 (11.9–12.5)	5.18 (4.60–5.76)	<0.001
V 1.7 (1.6-1.9) 1.4 (1.2-1.5) 1.3 (1.2-1.5) 1.2 (1.1-1.3) 1.2 (1.1-1.3) 1.1.43 (-1.86 to -0.07) 1.3 (1.2 (1.1-1.5)) 1.1.43 (-1.86 to -0.77) 1.3 (1.2 (1.1-1.5)) 1.1.43 (-1.86 to -0.77) 1.1.43 (-1.86 to -0.72) 1.1.43 (-1.86 to -0.72) 1.1.43 (-1.86 to -0.72) 1.1.43 (-1.86 to -0.72) 1.1.43 (-1.28 to -0.72) 1.1.43 (-1.28 to -0.72) 1.1.43 (-1.28 to -0.72) 1.1.43 (-1.28 to -0.72) 1.1.43 (-1.24 to 0.25) 1.1.43 (-1.47 to	≥65 y	43.3 (39.8–46.9)	46.4 (43.8–49.0)	59.3 (56.9–61.7)	1.81 (0.17–3.47)	43.3 (42.5–44.0)	46.5 (45.8–47.2)	68.5 (67.7–69.3)	2.46 (1.71–3.22)	<0.001
	Stroke									
18.0 (17.1-18.9) 16.8 (16.0-17.5) -2.02 (-3.06 to -0.97) 19.9 (19.5-20.3) 15.7 (15.4-16.0) 16.3 (16.0-16.7) -1.08 (-1.38 to -0.77) 204.3 216.9 -2.04 (-2.43 to -1.66) 430.3 (427.9-432.7) 256.5 (254.8-258.2) 248.9 (247.3-250.4) -2.82 (-3.47 to -2.16) 198.9-209.8) (212.3-221.5) -2.04 (-2.43 to -1.66) 430.3 (427.9-432.7) 256.5 (254.8-258.2) 248.9 (247.3-250.4) -2.82 (-3.47 to -2.16) 108.9-209.8) (212.3-221.5) -2.04 (-2.43 to -1.66) 430.3 (427.9-432.7) 256.5 (254.8-258.2) 248.9 (247.3-250.4) -2.82 (-3.47 to -2.16) 108.9-209.8) (212.3-221.5) -2.04 (-2.43 to -1.66) 3.6 (3.4-37.7) 266.5 (-2.47.5) -0.08 (-0.32 to 0.16) 10.3 (0.2-0.4) 0.4 (03-0.5) 0.48 (-5.47 to 6.81) 3.7 (36-3.77) 26.5 (26.1-26.9) -0.11 (-0.47 to 0.26) 14.1 (3.7-4.5) 59.1 (56.8-61.5) 1.18 (0.79-1.57) 259.2 (257.3-261.0) 237.7 (236.0-239.2) -0.18 (-1.22 to 0.32)	<45 y	1.7 (1.6–1.9)	1.4 (1.2–1.5)	1.3 (1.2–1.5)	-1.32 (-1.71 to -0.93)	1.5 (1.4–1.6)	1.2 (1.1–1.3)	1.2 (1.1–1.3)	-1.43 (-1.86 to -1.00)	0.04
204.3 216.9 -2.04 (-2.43 to -1.66) 430.3 (427.9-432.7) 256.5 (254.8-258.2) 248.9 (247.3-250.4) -2.82 (-3.47 to -2.16) (198.9-209.8) (212.3-221.5) -2.04 (-2.43 to -1.66) 430.3 (427.9-432.7) 256.5 (254.8-258.2) 248.9 (247.3-250.4) -2.82 (-3.47 to -2.16) (198.9-209.8) (212.3-221.5) 3.7 (3.6-3.3) 3.6 (3.4-3.7) 2.66.5 (25.3-261.4) -0.008 (-0.32 to 0.16) (13.7-4.5) 0.4 (03-0.5) 0.48 (-5.47 to 6.81) 3.7 (3.6-3.3) 3.6 (3.4-3.7) 2.6.5 (26.1-26.9) -0.011 (-0.47 to 0.26) 4.1 (3.7-4.5) 5.1 (4.7-5.5) 1.78 (0.00-3.60) 27.1 (26.6-27.6) 24.1 (23.7-24.5) 26.5 (26.1-26.9) -0.11 (-0.47 to 0.26) 5.2.2 (49.4-55.0) 59.1 (56.8-61.5) 1.18 (0.79-1.57) 259.2 (257.3-261.0) 237.7 (236.0-239.2) -0.46 (-1.22 to 0.32)	45–64 y	24.3 (22.9–25.8)	18.0 (17.1–18.9)	16.8 (16.0–17.5)	-2.02 (-3.06 to -0.97)	19.9 (19.5–20.3)	15.7 (15.4–16.0)	16.3 (16.0–16.7)	-1.08 (-1.38 to -0.77)	<0.001
0.3 (0.2 - 0.4) 0.4 (03 - 0.5) 0.48 (-5.47 to 6.81) 3.7 (3.6 - 3.8) 3.6 (3.4 - 3.7) 3.6 (3.5 - 3.7) -0.08 (-0.32 to 0.16) 4.1 (3.7 - 4.5) 5.1 (4.7 - 5.5) 1.78 (0.00 - 3.60) 27.1 (26.6 - 27.6) 24.1 (23.7 - 24.5) 26.5 (26.1 - 26.9) -0.11 (-0.47 to 0.26) 5.2.2 (49.4 - 55.0) 59.1 (56.8 - 61.5) 1.78 (0.00 - 3.60) 27.1 (26.6 - 27.6) 24.1 (23.7 - 24.5) 26.5 (26.1 - 26.9) -0.11 (-0.47 to 0.26)	≥65 y	316.9 (307.4–326.4)	204.3 (198.9–209.8)	216.9 (212.3–221.5)	-2.04 (-2.43 to -1.66)	430.3 (427.9–432.7)	256.5 (254.8–258.2)	248.9 (247.3–250.4)	–2.82 (–3.47 to –2.16)	<0.001
0.4 (0.3-0.5) 0.3 (0.2-0.4) 0.4 (03-0.5) 0.48 (-5.47 to 6.81) 3.7 (3.6-3.8) 3.6 (3.4-3.7) 3.6 (3.5-3.7) -0.08 (-0.32 to 0.16) y 3.9 (3.3-4.5) 4.1 (3.7-4.5) 5.1 (4.7-5.5) 1.78 (0.00-3.60) 27.1 (26.6-27.6) 24.1 (23.7-24.5) 26.5 (26.1-26.9) -0.11 (-0.47 to 0.26) 43.9 (40.4-47.4) 5.2 (49.4-55.0) 59.1 (56.8-61.5) 1.18 (0.79-1.57) 259.2 (257.3-261.0) 237.7 (236.0-239.3) 237.6 (236.1-239.2) -0.46 (-1.22 to 0.32)	Other cardic	wascular diseases								
y 3.9 (3.3-4.5) 4.1 (3.7-4.5) 1.7 (4.7-5.5) 1.7 (0.00-3.60) 27.1 (26.6-27.6) 24.1 (23.7-24.5) 26.5 (26.1-26.9) -0.11 (-0.47 to 0.26) 43.9 (40.4-47.4) 52.2 (49.4-55.0) 59.1 (56.8-61.5) 1.18 (0.79-1.57) 259.2 (257.3-261.0) 237.7 (236.0-239.3) 237.6 (236.1-239.2) -0.46 (-1.22 to 0.32)	<45 y	0.4 (0.3-0.5)	0.3 (0.2–0.4)	0.4 (03-0.5)	0.48 (-5.47 to 6.81)	3.7 (3.6–3.8)	3.6 (3.4–3.7)	3.6 (3.5–3.7)	-0.08 (-0.32 to 0.16)	0.25
43.9 (40.4-47.4) 52.2 (49.4-55.0) 59.1 (56.8-61.5) 1.18 (0.79-1.57) 259.2 (257.3-261.0) 237.7 (236.0-239.3) 237.6 (236.1-239.2) -0.46 (-1.22 to 0.32)	45–64 y	3.9 (3.3–4.5)	4.1 (3.7–4.5)	5.1 (4.7–5.5)	1.78 (0.00–3.60)	27.1 (26.6–27.6)	24.1 (23.7–24.5)	26.5 (26.1–26.9)	-0.11 (-0.47 to 0.26)	0.07
	≥65 y	43.9 (40.4–47.4)	52.2 (49.4–55.0)	59.1 (56.8-61.5)	1.18 (0.79–1.57)	259.2 (257.3–261.0)	237.7 (236.0–239.3)	237.6 (236.1–239.2)	-0.46 (-1.22 to 0.32)	0.01




Figure 2. Trends of age-adjusted mortality rates attributable to total cardiovascular disease and its components in Hispanic and Non-Hispanic White individuals stratified by age in the United States, 1999 to 2018. AAMR indicates age-adjusted mortality rate; and NH, non-Hispanic.

and decline in hypertension control.^{2,24-27} In a recent National Health and Nutrition Examination Survey study looking at participants with diabetes, between 2007 and 2018 the glycemic control that was achieved declined from 57.4% to 50.5%, and blood pressure control decreased from 74.2% to 70.4%, while lipid control leveled off.²⁸

Hispanic individuals were reported as the most physically inactive ethnic group in the United States.^{29,30} The recent Behavioral Risk Factor Surveillance System data showed that physical inactivity, hypertension, diabetes, and obesity remained substantially high among Hispanic men and women.³¹ Only 37% of all Hispanic adults had cholesterol levels checked, compared with 66% of NHW people.³² Mexican Americans also had a higher age-adjusted incidence of hemorrhagic stroke than NHW patients.³³ Suboptimal CVD risk factor profiles explain the current disparities related to CVD mortality, including the stroke mortality gap between NHW and Hispanic adults.

Stroke mortality decline was slower in Hispanic than NHW adults because of a rise in mortality between 2011 and 2018 in the former. Moreover, these aforementioned trends are further heightened across age groups. We noted deceleration in stroke mortality decline in younger Hispanic adults and increased mortality in older adults than NHW adults. Previously, the Brain Attack Surveillance in Corpus Christi Project

demonstrated a >2-fold increased incidence of stroke among Mexican Americans aged 45 to 49 years compared with NHW adults.³³ Among younger Hispanic adults, total CVD mortality and HF mortality was also on the rise compared with NHW individuals. These statistics reflect a growing CVD risk burden among younger Hispanic adults.³⁴ According to the National Health and Nutrition Examination Survey 2015 to 2016,³⁵ young Hispanic adults had a relatively higher prevalence of obesity (46.9% versus 38.2%) and diabetes (21.5% versus 13%) than NHW individuals. In the recent Young-MI registry, 18% of young Hispanic adults had possible or definite familial hypercholesterolemia.³⁶ Hispanic individuals lead the diabetic epidemic and are 1.5 times more likely to die of diabetes than NHW individuals.³⁷ According to the Behavioral Risk Factor Surveillance System data from 2015 to 2018, younger Hispanic adults had a higher prevalence of physical inactivity (31.7% versus 23.4%) than NHW adults.³¹ Childhood adiposity and obesity and youngonset diabetes^{38,39} are more prevalent in Hispanic than NHW adults. Besides, smoking was more prevalent in Hispanic youth (28% versus 23.8%) than in NHW adults.⁴⁰ These findings carry important public health implications and must be addressed to curb the growing CVD burden in the young Hispanic population.

Recent data have shown widespread urban-rural gaps in CVD mortality across all ethnic and racial

anic and Non-Hispanic White Adults in the United States Stratified by Sex, 1999 to 2018	
. Trends in Cardiovascular Disease Mortality Between Hispanic and Non-H	
Table 3	

Age-adjusted mort Age-adjusted mort Total cardiovascular disease Total cardiovascular disease Women 227.6 (224.0-231.2) Men 227.6 (315.3-325.9) Men 320.6 (315.3-325.9) Men 133.1 (130.4-135.9) Men 133.1 (130.4-135.9) Men 200.1 (195.9-204.3) Heart failure 200.1 (195.9-204.3)	l morta 231.2) 325.9) 35.9) 35.9)	Age-adjusted mortality rate (95% CI) 1999 2011 1999 2011 scular disease 2011 227.6 (224.0-231.2) 140.9 (138.8-142.9) 320.6 (315.3-325.9) 198.1 (195.2-200.9) 320.6 (315.3-325.9) 198.1 (195.2-200.9) disease	2018 2018.1 128.1 (126.5–129.7) 191.6 (189.3–193.9)	AAPC (95% CI) (1999–2018) -2.97 (-3.38 to -2.56) -2.70 (-3.00 to -2.39)	Age-adjusted mortality rate (95% Cl) 1999 2011	lity rate (95% CI)		AAPC (95% CI)	Test for parallelism
	231.2) 235.9) 325.9) 35.9) 204.3)	011 40.9 (138.8–142.9) 98.1 (195.2–200.9) 5.7 (64.3–67.1) 77.7 (105.5–109.8)	2018 128.1 (126.5–129.7) 191.6 (189.3–193.9)	(1999–2018) -2.97 (–3.38 to –2.56) -2.70 (–3.00 to –2.39)	1999				
	231.2) 325.9) 35.9) 204.3)	40.9 (138.8–142.9) 98.1 (195.2–200.9) 5.7 (64.3–67.1) 77.7 (105.5–109.8)	128.1 (126.5–129.7) 191.6 (189.3–193.9)	-2.97 (-3.38 to -2.56) -2.70 (-3.00 to -2.39)		2011	2018	(1999–2018)	P value
		40.9 (138.8–142.9) 98.1 (195.2–200.9) 5.7 (64.3–67.1) 77.7 (105.5–109.8)	128.1 (126.5–129.7) 191.6 (189.3–193.9)	-2.97 (-3.38 to -2.56) -2.70 (-3.00 to -2.39)		_	_		
		98.1 (195.2–200.9) 6.7 (64.3–67.1) 77.7 (105.5–109.8)	191.6 (189.3–193.9)	-2.70 (-3.00 to -2.39)	271.5 (270.6–272.3)	174.5 (173.9–175.2)	164 (163.4–164.7)	-2.58 (-3.16 to -2.00)	<0.001
		5.7 (64.3–67.1) 27.7 (105.5–109.8)			389.7 (388.4–391.1)	256.8 (255.8–257.7)	245.7 (244.8–246.6)	-2.37 (-2.67 to -2.07)	<0.001
		5.7 (64.3–67.1) 07.7 (105.5–109.8)							
		07.7 (105.5–109.8)	50.3 (49.3–51.3)	-5.01 (-5.54 to -4.49)	150.8 (150.1–151.4)	81.0 (80.5–81.4)	64.9 (64.6–65.3)	-4.38 (-4.72 to -4.04)	<0.001
Heart failure			92.9 (91.3–94.5)	-4.18 (-4.64 to -3.71)	253.0 (251.9–254.1)	149.4 (148.6–150.1)	128.6 (128.0–129.2)	–3.51 (–3.86 to –3.15)	<0.001
Women 10.6 (9.8–11.4)		9.2 (8.7–9.7)	10.4 (9.9–10.8)	0.08 (-1.31 to 1.48)	19.6 (19.3–19.8)	16.2 (16.0–16.4)	19.4 (19.2–19.6)	-0.00 (-0.62 to 0.61)	0.82
Men 11.7 (10.6–12.8)		11.2 (10.5–11.9)	13.8 (13.2–14.4)	1.00 (0.19–1.82)	21.7 (21.4–22.1)	19.3 (19.0–19.5)	24.6 (24.3–24.9)	0.67 (0.24–1.10)	0.01
Hypertensive heart disease									
Women 6.6 (6.0–7.2)	6.	6.6 (6.2–7.0)	7.9 (7.5, 8.2)	1.25 (0.03–2.48)	6.5 (6.4–6.7)	7.3 (7.2–7.5)	10.3 (10.1–10.5)	2.42 (1.95–2.90)	<0.001
Men 7.1 (6.3–7.8)	8.	8.9 (8.3–9.4)	11.8 (11.2, 12.3)	2.32 (–0.13 to 4.83)	6.7 (6.5–6.8)	9.4 (9.3–9.6)	13.7 (13.5–13.9)	3.90 (3.33–4.48)	<0.001
Stroke									
Women 42.2 (40.7–43.7)		29.0 (28.1–29.9)	29.9 (29.1–30.6)	-1.98 (-2.39 to -1.57)	58.4 (58.0–58.8)	36.5 (36.2–36.8)	35.5 (35.2–35.8)	-2.53 (-3.13 to -1.92)	<0.001
Men 52.6 (50.5–54.8)		32.6 (31.5–33.8)	34.2 (33.2–35.1)	-2.19 (-2.51 to -1.88)	60.8 (60.2–61.3)	36.1 (35.8–36.5)	35.6 (35.3–35.9)	-2.78 (-3.27 to -2.28)	<0.001
Other cardiovascular diseases	es								
Women 19.4 (18.4–20.4)		18.0 (17.3–18.7)	16.9 (16.3–17.5)	-0.60 (-0.82 to -0.38)	36.1 (35.8–36.5)	33.5 (33.2–33.8)	33.8 (33.6–34.1)	-0.29 (-0.75 to 0.17)	0.01
Men 28.7 (27.2–30.2)		23.0 (22.0–23.9)	22.1 (21.3–22.9)	-1.18 (-2.11 to -0.24)	47.6 (47.1–48.0)	42.6 (42.2–43.0)	43.2 (42.8–43.6)	-0.38 (-0.66 to -0.09)	0.01




Figure 3. Trends of age-adjusted mortality rates attributable to total cardiovascular disease and its components in Hispanic and Non-Hispanic White individuals stratified by sex in the United States, 1999 to 2018. AAMR indicates age-adjusted mortality rate; and NH, non-Hispanic.

groups.⁴¹ We also noted disparities between urban and rural counties regarding mortality among both study groups. For instance, large metros showed that stroke mortality has increased at a higher pace in Hispanic versus NHW residents. Given immigration policies, Hispanic immigrants' settlement in urban counties might have influenced these trends.⁴² That said, considering that Hispanic ethnicity was not universally recorded on death certificates^{41,43} from all states, Hispanic mortality in rural regions could be underestimated.

Hispanic individuals disproportionally face low quality of daily life and health disparities,^{4,44} secondary to suboptimal CVD profile and less favorable social determinants of health.^{4,45} Between 2011 and 2018, Hispanic individuals demonstrated a rise in financial deprivation, health coverage challenges, unemployment, and limited health literacy.³¹ However, despite having a socioeconomically challenged profile, overall Hispanic individuals exhibited better life expectancy than NHW individuals. That said, the controversial Hispanic paradox is an epidemiological observation with potential hazardous implications.⁴ Since the Hispanic paradox implies that Hispanic individuals are less susceptible to CVD than the general population, subsequent suboptimal risk assessment and delays in adequate CVD treatments can further compound the existing poor cardiovascular health among the Hispanic population. Moreover, studies have shown that paradoxical mortality trends, even if true, are not consistent across every Hispanic subgroup. For instance, Mexican adults had lower CVD mortality rates than NHW individuals, while Puerto Rican adults had similar mortality patterns to NHW adults.¹⁶ We noted that disaggregating analysis by demographic characteristics and causespecific CVD revealed considerable heterogeneities, especially regarding stroke and total CVD mortality in young Hispanic adults. Therefore, cardiovascular research that lumps diverse Hispanic populations under 1 classification can mask significant differences in the cardiovascular health spectrum of the Hispanic population.4

Our study findings have several shortcomings. This report serves as a "deep dive" comprehensive characterization of CVD mortality trends for the overall Hispanic population in comparison with the NHW population, but we could not analyze according to specific Hispanic subgroups. As discussed before, prior literature has shown variation in CVD mortality across the 3 largest Hispanic subgroups in the United States (Puerto Rican, Cuban,

					Non-Hispanic White adults	adults			
	Age-adjusted mortality rate (95% Cl)	lity rate (95% Cl)		AAPC (95% CI)	Age-adjusted mortality rate (95% CI)	lity rate (95% CI)		AAPC (95% CI)	Test for parallelism
	1999	2011	2018	(1999–2018)	1999	2011	2018	(1999–2018)	P value
Total cardiovascular disease	cular disease								
Large metro	265.4 (261.8–269.0)	164.9 (162.8–166.9)	156.0 (154.4–157.6)	-2.79 (-3.16 to -2.41)	320.0 (318.9–321.0)	202.5 (201.7–203.3)	191.3 (190.5–192.0)	-2.64 (-3.11 to -2.18)	<0.001
Medium- small metro	262.5 (256.4–268.6)	169.4 (166.0–172.7)	158.2 (155.6–160.9)	-2.56 (-3.04 to -2.07)	316.1 (314.8–317.4)	209.7 (208.8–210.7)	201.5 (200.6–202.4)	-2.33 (-2.72 to -1.95)	<0.001
Rural	307.6 (295.7–319.5)	172.6 (166.1–179.1)	158.1 (152.9–163.2)	-3.05 (-3.68 to -2.43)	340.0 (338.3–341.6)	236.7 (235.3–238.0)	227.0 (225.8–228.3)	–2.13 (–2.32 to –1.94)	<0.001
Ischemic heart disease	disease								
Large metro	166.7 (163.8–169.5)	85.7 (84.2–87.2)	68.3 (67.3–69.4)	-4.65 (-5.07 to -4.22)	201.1 (200.3–202.0)	109.2 (108.6–109.7)	89.2 (88.7–89.7)	-4.18 (-4.59 to -3.76)	<0.001
Medium- small metro	146.4 (141.9–150.9)	79.4 (77.1–81.7)	70.6 (68.8–72.4)	-3.78 (-4.36 to -3.20)	182.7 (181.7–183.7)	107.1 (106.4–107.8)	91.3 (90.7–91.9)	-3.63 (-3.95 to -3.31)	<0.001
Rural	171.6 (162.7–180.4)	86.4 (81.8–91.0)	71.7 (68.3–75.2)	-4.21 (-4.93 to -3.47)	196.8 (195.6–198.1)	122.7 (121.8–123.7)	108.3 (107.4–109.2)	-3.15 (-3.36 to -2.94)	<0.001
Heart failure									
Large metro	9.3 (8.6–10.0)	9.6 (9.1–10.1)	11.7 (11.2–12.1)	1.37 (0.87–1.88)	17.5 (17.3–17.7)	16.0 (15.8–16.2)	21.2 (20.9–21.4)	1.08 (0.44–1.72)	<0.001
Medium- small metro	13.1 (11.7–14.6)	10.2 (9.4–11.1)	11.5 (10.8–12.3)	-0.30 (-1.87 to 1.29)	21.2 (20.8–21.5)	17.5 (17.2–17.7)	21.2 (20.9–21.4)	0.04 (-0.50 to 0.58)	0.72
Rural	21.3 (18.0–24.6)	13.9 (12.0–15.8)	15.0 (13.4–16.7)	-1.50 (-5.25 to 2.41)	26.8 (26.4–27.3)	21.1 (20.7–21.5)	24.1 (23.7–24.5)	-0.60 (-1.16 to -0.04)	0.02
Hypertensive heart disease	eart disease								
Large metro	Large metro 7.4 (6.9–8.0)	7.9 (7.4–8.3)	10.4 (10.0–10.8)	1.95 (0.56–3.35)	7.4 (7.3–7.6)	9.3 (9.1–9.4)	12.0 (11.8–12.2)	2.62 (2.06–3.18)	<0.001
Medium- small metro	6.2 (5.2–7.1)	8.2 (7.5–9.0)	8.8 (8.2–9.4)	0.96 (0.34–1.59)	6.7 (6.5–6.9)	8.2 (8.0–8.4)	12.4 (12.2–12.7)	2.86 (2.29–3.44)	<0.001
Rural	4.9 (3.5–6.6)	5.0 (4.0-6.3)	6.0 (5.0–6.9)	1.37 (0.16–2.60)	5.6 (5.4–5.8)	7.2 (7.0–7.4)	11.5 (11.3–11.8)	3.94 (3.51–4.36)	<0.001
Stroke									
Large metro	43.4 (42.0–44.9)	29.1 (28.3–30.0)	32.6 (31.8–33.3)	-1.71 (-2.25 to -1.18)	56.2 (55.7–56.6)	33.5 (33.2–33.8)	34.3 (34.0–34.6)	-2.53 (-3.33 to -1.72)	<0.001
Medium- small metro	51.6 (48.9–54.3)	34.5 (32.9–36.0)	31.3 (30.1–32.5)	-2.64 (-3.10 to -2.18)	61.6 (61.0–62.1)	37.9 (37.5–38.3)	36.4 (36.1–36.8)	-2.70 (-3.22 to -2.18)	<0.001
Rural	60.2 (54.9–65.5)	32.8 (30.0–35.7)	29.0 (26.8–31.2)	-3.76 (-5.00 to -2.51)	65.7 (64.9–66.4)	42.5 (42.0–43.1)	38.8 (38.2–39.3)	-2.70 (-3.12 to -2.28)	<0.001
ther cardiova:	Other cardiovascular diseases								
Large metro	Large metro 21.8 (20.9–22.8)	19.3 (18.7–20.0)	18.5 (18.0–19.1)	-0.53 (-0.72 to -0.34)	37.7 (37.4–38.1)	34.6 (34.3–34.9)	34.6 (34.3–34.9)	-0.38 (-0.79 to 0.03)	0.02
Medium- small metro	25.6 (23.7–27.4)	22.3 (21.1–23.5)	20.1 (19.1–21.0)	-1.17 (-1.48 to -0.86)	43.9 (43.5–44.4)	39.1 (38.7–39.5)	40.2 (39.8–40.6)	-0.35 (-0.67 to -0.03)	<0.001
Bural	201 /067_23 E)								

AAPC indicates average annual percent change.

and Mexican individuals).¹⁶ However, our data are more recent, and we focused on sex and age interactions to demonstrate variations in CVD mortality. We could not measure the influence of migration status, acculturation metrics, or socioeconomic differences on CVD mortality statistics. On the same note, we could not draw a formal correlation between cardiovascular risk factors and mortality because of a lack of clinical variables in this data set. Data were also limited to test the hypothesis of role of any potential protective factors in relation to better survival trends among the Hispanic population. Vital statistics and census population data rely on death certificates, which are subject to miscoding, especially potential misclassification of race and ethnicity may lead to under- or overreporting of mortality rates.⁴⁶ Nevertheless, despite these limitations, this study provides a comprehensive comparative analysis of trends in CVD mortality and its subtypes between Hispanic individuals and NHW adults, overall and stratified by age, sex, and region subgroups.

In summary, between 1999 and 2018, we unmasked some heterogeneities in CVD mortality between Hispanic and NHW adults. Considering that Hispanic ethnicity individuals are the fastest-growing population segment, future research and health endeavors should focus on developing culturally appropriate interventions to prevent modifiable CVD risk factors, adherence to evidence-based treatment strategies, and addressing social and health inequalities to bend the current CVD death trajectories in vulnerable Hispanic subgroups.

ARTICLE INFORMATION

Received August 3, 2021; accepted January 31, 2022.

Affiliations

Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX (S.U.K., M.C.); Department of Cardiovascular Medicine, Guthrie Health System/Robert Packer Hospital, Sayre, PA (A.N.L.); Department of Medicine, Erie County Medical Center, Buffalo, NY (S.H.Y.); Division of Cardiology, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, MA (S.S.D.); Department of Cardiovascular Medicine, West Virginia University, Morgantown, WV (M.Z.K.); Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA (K.E.W.); Division of Cardiology and the Cardiovascular Institute, Stanford University, Stanford, CA (F.R.); Center for Outcomes Research, Houston Methodist, Houston, TX (M.C.); and Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD (E.D.M.).

Sources of Funding

Dr Michos is supported by the Amato Fund for Women's Cardiovascular Health research at Johns Hopkins University. Dr Michos is additionally supported by the American Heart Association Strategic Focused Research Network grant 20SFRN35380046. Dr Rodriguez is supported by the National Heart, Lung, and Blood Institite K01 HL 144607 (FRR) and the American Heart Association/Robert Wood Johnson Harold Amos Medical Faculty Development Program.

Disclosures

Dr Michos also has served on Advisory Boards for Astra Zeneca, Amarin, Bayer, Boehringer Ingelheim, Novo Nordisk, Novartis, and Esperion. The remaining authors have no disclosures to report.

Supplemental Material

Data S1 Tables S1–S4

REFERENCES

- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. *Circulation*. 2016;133:e38–e360. doi: 10.1161/CIR.00000 00000000350
- Sidney S, Quesenberry CP, Jaffe MG, Sorel M, Nguyen-Huynh MN, Kushi LH, Go AS, Rana JS. Recent trends in cardiovascular mortality in the United States and public health goals. *JAMA Cardiol.* 2016;1:594.– 599. doi: 10.1001/jamacardio.2016.1326
- Pearson-Stuttard J, Guzman-Castillo M, Penalvo JL, Rehm CD, Afshin A, Danaei G, Kypridemos C, Gaziano T, Mozaffarian D, Capewell S, et al. Modeling future cardiovascular disease mortality in the United States: national trends and racial and ethnic disparities. *Circulation*. 2016;133:967–978. doi: 10.1161/CIRCULATIONAHA.115.019904
- Rodriguez CJ, Allison M, Daviglus ML, Isasi CR, Keller C, Leira EC, Palaniappan L, Piña IL, Ramirez SM, Rodriguez B, et al. Status of cardiovascular disease and stroke in Hispanics/Latinos in the United States: a science advisory from the American Heart Association. *Circulation*. 2014;130:593–625. doi: 10.1161/CIR.00000000000000001
- 5. Ortman JM, Guarneri CE. United States population projections: 2000 to 2050. *United States Census Bureau*. 2000;1–19.
- Iribarren C, Darbinian JA, Fireman BH, Burchard EG. Birthplace and mortality among insured Latinos: the paradox revisited. *Ethn Dis.* 2009;19:185–191.
- Swenson CJ, Trepka MJ, Rewers MJ, Scarbro S, Hiatt WR, Hamman RF. Cardiovascular disease mortality in Hispanics and non-Hispanic Whites. *Am J Epidemiol.* 2002;156:919–928. doi: 10.1093/aje/ kwf140
- Willey JZ, Rodriguez CJ, Moon YP, Paik MC, Di Tullio MR, Homma S, Sacco RL, Elkind MS. Coronary death and myocardial infarction among Hispanics in the Northern Manhattan Study: exploring the Hispanic paradox. *Ann Epidemiol.* 2012;22:303–309. doi: 10.1016/j.annep idem.2012.02.014
- Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP, Hazuda HP. All-cause and cardiovascular mortality among Mexican-American and non-Hispanic White older participants in the San Antonio Heart Study- evidence against the "Hispanic paradox." Am J Epidemiol. 2003;158:1048–1057. doi: 10.1093/aje/kwg249
- Pandey DK, Labarthe DR, Goff DC, Chan W, Nichaman MZ. Communitywide coronary heart disease mortality in Mexican Americans equals or exceeds that in non-Hispanic Whites: the Corpus Christi Heart Project. *Am J Med*. 2001;110:81–87. doi: 10.1016/S0002-9343(00)00667-7
- CDC Wide-ranging ONline Data for Epidemiologic Research (https:// wonder.cdc.gov/). Accessed November 2, 2020.
- Grieco EC, Grieco EM, Cassidy RC. Overview of race and Hispanic origin, 2000: US Department of Commerce, Economics and Statistics Administration, US...; 2001.
- National Center for Health Statistics, death 1999-2018 (https://wonder. cdc.gov/wonder/help/ucd.html) Accessed February 10, 2020.
- Brooks EG, Reed KD. Principles and pitfalls: a guide to death certification. *Clin Med Res.* 2015;13:74–84. doi: 10.3121/cmr.2015.1276
- Shah NS, Molsberry R, Rana JS, Sidney S, Capewell S, O'Flaherty M, Carnethon M, Lloyd-Jones DM, Khan SS. Heterogeneous trends in burden of heart disease mortality by subtypes in the United States, 1999–2018: observational analysis of vital statistics. *BMJ*. 2020;370:1999–2018. doi: 10.1136/bmj.m2688
- Rodriguez F, Hastings KG, Boothroyd DB, Echeverria S, Lopez L, Cullen M, Harrington RA, Palaniappan LP. Disaggregation of cause-specific cardiovascular disease mortality among Hispanic subgroups. *JAMA Cardiol.* 2017;2:240–247. doi: 10.1001/jamacardio.2016.4653
- Cross SH, Mehra MR, Bhatt DL, Nasir K, O'Donnell CJ, Califf RM, Warraich HJ. Rural-urban differences in cardiovascular mortality in the US, 1999–2017. *JAMA*. 2020;323:1852–1854. doi: 10.1001/ jama.2020.2047
- Anderson RN, Rosenberg HM. Age standardization of death rates: implementation of the year 2000 standard. *Natl Vital Stat Rep.* 1998;47.

- Woolf SH, Schoomaker H. Life expectancy and mortality rates in the United States, 1959–2017. JAMA. 2019;322:1996–2016. doi: 10.1001/ jama.2019.16932
- Khan SU, Bashir ZS, Khan MZ, Khan MS, Gulati M, Blankstein R, Blumenthal RS, Michos ED. Trends in cardiovascular deaths among young adults in the United States, 1999 to 2018. *Am J Cardiol.* 2020;128:216–217. doi: 10.1016/j.amjcard.2020.05.014
- Kim H-J, Fay MP, Yu B, Barrett MJ, Feuer EJ. Comparability of segmented line regression models. *Biometrics*. 2004;60:1005–1014. doi: 10.1111/j.0006-341X.2004.00256.x
- Lopez AD, Adair T. Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics. *Int J Epidemiol*. 2019;48:1815–1823. doi: 10.1093/ije/dyz143
- Curtin SC. Trends in cancer and heart disease death rates among adults aged 45–64: United States, 1999–2017. Natl Vital Stat Rep. 2019;68:1–9.
- Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011–2016. JAMA. 2020;323:2526–2528. doi: 10.1001/jama.2020.4501
- Muntner P, Hardy ST, Fine LJ, Jaeger BC, Wozniak G, Levitan EB, Colantonio LD. Trends in blood pressure control among US adults with hypertension, 1999–2000 to 2017–2018. *JAMA*. 2020;324:1190–1200. doi: 10.1001/jama.2020.14545
- Khan SS, Greenland P. Comprehensive cardiovascular health promotion for successful prevention of cardiovascular disease. *JAMA*. 2020;324:2036–2037. doi: 10.1001/jama.2020.18731
- Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G. Prevalence of prediabetes among adolescents and young adults in the United States, 2005–2016. *JAMA Pediatr.* 2020;174:e194498. doi: 10.1001/jamapediat rics.2019.4498
- Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in U.S. adults, 1999-2018. N Engl J Med. 2021;384:2219–2228. doi: 10.1056/NEJMsa2032271
- 29. Ham SA, Yore MM, Kruger J, Heath GW, Moeti R. Physical activity patterns among Latinos in the United States: putting the pieces together. *Prev Chronic Dis.* 2007;4:A92.
- Chowdhury PP, Balluz L, Okoro C, Strine T. Leading health indicators: a comparison of Hispanics with non-Hispanic Whites and non-Hispanic Blacks, United States 2003. *Ethn Dis.* 2006;16:534–541.
- The Behavioral Risk Factor Surveillance System (BRFSS) Prevalence and Trends Data (https://www.cdc.gov/brfss/brfssprevalence/index. html). Accessed November 18, 2020.
- Nelson K, Norris K, Mangione CM. Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey. *Arch Intern Med.* 2002;162:929–935. doi: 10.1001/archinte.162.8.929
- Morgenstern LB, Smith MA, Lisabeth LD, Risser JM, Uchino K, Garcia N, Longwell PJ, McFarling DA, Akuwumi O, Al-Wabil A, et al. Excess stroke in Mexican Americans compared with non-Hispanic Whites: the brain attack surveillance in Corpus Christi Project. *Am J Epidemiol.* 2004;160:376–383. doi: 10.1093/aje/kwh225

- PéRez-Escamilla R, Putnik P. The role of acculturation in nutrition, lifestyle, and incidence of type 2 diabetes among Latinos. *J Nutr.* 2007;137:860–870. doi: 10.1093/jn/137.4.860
- 35. NHANES National Health and Nutrition Examination Survey Homepage. 2021;2021.
- Singh A, Gupta A, Collins BL, Qamar A, Monda KL, Biery D, Lopez JAG, de Ferranti SD, Plutzky J, Cannon CP, et al. Familial hypercholesterolemia among young adults with myocardial infarction. *J Am Coll Cardiol.* 2019;73:2439–2450. doi: 10.1016/j.jacc.2019.02.059
- Caballero AE. Type 2 diabetes in the Hispanic or Latino population: challenges and opportunities. *Curr Opin Endocrinol Diabetes Obes*. 2007;14:151–157. doi: 10.1097/MED.0b013e32809f9531
- Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, Srinivasan SR, Daniels SR, Davis PH, Chen W, et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. *N Engl J Med.* 2011;365:1876–1885. doi: 10.1056/NEJMoa1010112
- Daviglus ML, Pirzada A, Talavera GA. Cardiovascular disease risk factors in the Hispanic/Latino population: lessons from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Prog Cardiovasc Dis. 2014;57:230–236. doi: 10.1016/j.pcad.2014.07.006
- Johnston LD, O'Malley PM, Bachman GG, Scholenberg JE. Monitoring the Future: National Survey Results on Drug Use, 1975–2006, I, Secondary School Students, Bethesda, MD. National Institute on Drug Abuse NIH Publication No 07-6205. Volume I, Secondary School Students.
- Vaughan AS, Ritchey MD, Hannan J, Kramer MR, Casper M. Widespread recent increases in county-level heart disease mortality across age groups. *Ann Epidemiol.* 2017;27:796–800. doi: 10.1016/j. annepidem.2017.10.012
- Khan SU, Kalra A, Yedlapati SH, Dani SS, Shapiro MD, Nasir K, Virani SS, Michos ED, Alkhouli M. Stroke-related mortality in the United States–Mexico border area of the United States, to 2018. J Am Heart Assoc. 1999;2021:e019993. doi: 10.1161/ JAHA.120.019993
- Casper M, Kramer MR, Quick H, Schieb LJ, Vaughan AS, Greer S. Changes in the geographic patterns of heart disease mortality in the United States. *Circulation*. 2016;133:1171–1180. doi: 10.1161/CIRCU LATIONAHA.115.018663
- Mitrani V. Reducing health disparities for Hispanics through the development of culturally tailored interventions. *Hisp Health Care Int.* 2009;7:2–4. doi: 10.1891/1540-4153.7.1.2
- 45. Daviglus ML, Talavera GA, Avilés-Santa ML, Allison M, Cai J, Criqui MH, Gellman M, Giachello AL, Gouskova N, Kaplan RC, et al. Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States. *JAMA*. 2012;308:1775–1784. doi: 10.1001/jama.2012.14517
- Rosenberg HM, Maurer JD, Sorlie PD, Johnson NJ, MacDorman MF, Hoyert DL, Spitler JF, Scott C. Quality of death rates by race and Hispanic origin: a summary of current research, 1999. *Vital Health Stat.* 1999;2:1–13.

Supplemental Material

Data S1.

Supplemental Methods

The year 1999 population estimates are bridged-race intercensal estimates of the July 1 resident population, based on the year 1990 and 2000 census counts.¹⁸ The year 2000 and year 2010 population estimates are April 1 modified census counts, with bridged-race categories. The 2001-2009 population estimates are bridged-race revised intercensal estimates of the July 1 resident population, based on the year 2000 and the year 2010 census counts (released by NCHS on 10/26/2012). The 2001-2009 archive population estimates are bridged-race postcensal estimates of the July 1 resident population. The 2011-2018 population estimates are bridged-race postcensal estimates of the July 1 resident population.

We estimated age-adjusted (to the 2000 US standard population)¹⁸ mortality rates for each year per 100,000 population within the county, across the counties within a particular state, and across the entire US. Utilizing this approach, we suppressed rates for data demonstrating zero to nine (0-9) deaths along with the corresponding denominator population when the population showed fewer than 10 persons. For deaths less than 20, rates were considered unreliable and were not computed during the estimation of age-adjusted rates. Since we aggregated death rates across counties, all counties were included regardless of population size and death counts.

We analyzed temporal trends by fitting log-linear regression models using the Joinpoint Regression Program version 4.7.0.0 (National Cancer Institute). We calculated average annual percentage rate change (AAPC) with 95% confidence intervals (CIs) in age-adjusted mortality rates for all analyses from 1999 to 2018, further divided into 1999-2011 and 2011-2018, weighted to account for differences in the number of inflection points.^{15, 19} We identified the year 2011 as the inflection point in total CVD mortality trends – consistent with prior studies reporting national CVD mortality trends.^{15, 20} We applied following settings to Joinpoint Regression: (i) Grid search method: 2, 2, 0; (ii) number of joinpoints: 0 to 3; (iii) model selection method: Permutation test; and (iv) annual percent change/AAPC/Tau CIs estimation: Parametric method.²¹ Slopes were considered increasing or decreasing if the estimated slope differed significantly from zero.^{19, 21} We applied a specific procedure- comparability test to determine whether two regression mean functions are parallel due to different intercepts (test of parallelism)²². Analyses were stratified by age (<45 years, 45-64 years, and ≥ 65 years), as well as by sex, and urbanicity. For all analyses, statistical significance was set at 5%. Table S1. Average annual percent change in age-adjusted mortality rates in Hispanic and Non-Hispanic White adults attributed to cardiovascular diseases.

	Hispan	ic adults	Non-Hispanic	White adults
	(1999 – 2011)	(2011 – 2018)	(1999 – 2011)	(2011 – 2018)
Total CVD	-3.88 (-4.26, -3.49)*	-0.86 (-1.26, -0.45)*	-3.42 (-3.79, -3.05)*	-0.63 (-0.88, -0.38)*
Ischemic heart disease	-5.20 (-6.57, -3.80)*	-3.07 (-3.67, -2.47)*	-4.52 (-4.89, -4.14)*	-2.47 (-4.89, -4.14)*
Heart failure	-0.86 (-2.05, 0.35)	3.09 (1.93, 4.26)*	-1.31(-2.16, -0.46)*	3.21 (2.53, 3.90)*
Hypertensive heart	1.45 (-0.51, 3.46)	2.60 (0.64, 4.60)*	1.93 (1.58, 2.28)*	5.04 (3.77, 6.33)*
disease				
Stroke	-3.67 (-3.95, -3.39)*	0.79 (0.03, 1.56)*	-4.10 (-5.00, -3.19)*	-0.09 (-0.51, 0.33)
Other CVD	-0.97 (-1.25, -0.69)*	-0.90 (-2.71, 0.93)	-0.75 (-1.12, -0.37)*	0.30 (-1.59, 2.22)

*indicates that the average annual percent change is significantly different from zero (P<0.05). CVD = cardiovascular disease Table S2. Average annual percent change in age-adjusted mortality rates in Hispanic and Non-Hispanic White adults attributed to cardiovascular diseases stratified by age.

		Average annual perc	ent change (95% CI)	
	Hispani	c adults	Non-Hispanic	White adults
	(1999 – 2011)	(2011 – 2018)	(1999 – 2011)	(2011 – 2018)
Total CVD				
<45 y	-1.57 (-2.1, -0.96)*	1.14 (0.57, 1.71)*	-0.46 (-0.88, -0.01)*	-0.46 (-0.90, -0.02)*
45-64 y	-3.11 (-3.27, -2.95)*	-0.26 (-0.70, 0.19)	-2.18 (-2.43, -1.93)*	0.29 (0.10, 0.48)*
≥65 y	-4.05 (-4.47, -3.63)*	-1.03 (-1.47, -0.59)*	-3.70 (-4.06, -3.34)*	-0.80 (-1.04, -0.55)*
Ischemic heart disease				
<45 y	-1.49 (-3.67, 0.74)	0.68 (-0.25, 1.63)	-1.30 (-1.77, -0.83) *	-2.76 (-2.93, -2.58)*
45-64 y	-4.43 (-4.57, -4.09)*	-1.31 (-1.90, -0.72)*	-3.11 (-3.32, -2.90) *	-0.99 (-1.15, -0.84)*
≥65 y	-5.56 (-6.10, -5.03)*	-3.18 (-3.75, -2.61)*	-4.91 (-3.07, -2.49) *	-2.78 (-3.07, -2.49)*
Heart failure				
<45 y	1.42 (-1.12, 4.02)	7.53 (3.50, 11.71)*	0.01 (-0.53, 0.54)	5.96 (3.90, 8.06) *
45-64 y	-0.08 (-0.98, 0.82)	5.45 (2.85, 8.11)*	-0.94 (-1.58, -0.29)	5.95 (4.40, 7.52) *
≥65 y	-0.91 (-2.24, 0.45)	2.86 (1.56, 4.18)*	-1.37 (-2.19, -0.54) *	3.09 (2.43, 3.76)*
Hypertensive heart disease				
<45 y	2.83 (-0.19, 5.95)	6.07 (3.36, 8.84)*	6.05 (4.97, 7.14) *	3.60 (3.22, 3.97)*
45-64 y	3.12 (1.06, 5.22)*	0.35 (-0.25, 0.94)	5.86 (5.03, 6.70) *	4.05 (3.72,4.38) *
≥65 y	1.14 (-1.93, 4.31)	3.09 (0.75, 5.49)*	0.76 (0.41, 1.11) *	5.33 (3.17, 7.54)*
Stroke				
<45 y	-1.63 (-2.31, -0.94)*	-0.53 (-2.35, 1.32)	-1.85 (-3.89, 0.24)	0.31 (1.77, 2.44)*
45-64 y	-2.98 (-3.40, -2.57)*	-0.48 (-2.45, 1.53)	-2.24 (-2.52, -1.96)*	0.59 (0.24, 0.94)*
≥65 y	-3.81 (-4.11, -3.50)*	1.06 (0.21, 1.91)*	-4.33 (-5.32, -3.34)*	-0.16 (-0.59, 0.26)
Other CVD				
<45 y	-2.39 (-10.97, 7.02)	5.95 (2.86, 9.13)*	-0.40 (-0.75, -0.05) *	0.75 (-0.20, 1.70)
45-64 y	-0.11 (-2.03, 1.84)	3.53 (2.69, 4.37)*	-0.99 (-1.17, -0.81) *	1.42 (0.67, 2.18) *
≥65 y	1.83 (0.89, 2.77)*	0.75 (0.43, 1.07)*	-0.71 (-1.12, -0.30) *	-0.00 (-2.09, 2.12)

* indicates that the average annual percent change is significantly different from zero (P<0.05). CVD = cardiovascular disease, y = year Table S3. Average annual percent change in age-adjusted mortality rates in Hispanic and Non-Hispanic White adults attributed to cardiovascular diseases stratified by sex.

		Average annual per	cent change (95% CI)	
	Hispani	c adults	Non-Hispanic	White adults
	(1999 – 2011)	(2011 – 2018)	(1999 – 2011)	(2011 – 2018)
Total CVD				
Women	-3.84 (-4.29, -3.38)*	-1.27 (-1.68, -0.85)*	-3.61 (-4.26, -2.96)*	-0.77 (-1.34, -0.20)*
Men	-3.73 (-4.60, -2.86)*	-0.82 (-1.19, -0.45)*	-3.37 (-3.64, -3.11)*	-0.61 (-0.79, -0.43)*
Ischemic heart disease				
Women	-5.64 (-6.18, -5.10)*	-3.78 (-4.33, -3.22)*	-4.99 (-5.43, -4.54) *	-3.20 (-3.71, -2.68)*
Men	-5.04 (-5.66, -4.42)*	-2.30 (-2.96, -1.63)*	-4.28 (-4.66, -3.90) *	-2.15 (-2.41, -1.90)*
Heart failure				
Women	-1.33 (-2.62, -0.03)*	2.73 (1.75, 3.72)*	-1.65 (-2.49, -0.80) *	2.80 (2.18, 3.42)*
Men	-0.24 (-0.75, 0.28)	3.20 (1.42, 5.02)*	-1.20 (-1.64, -0.76) *	3.95 (2.91, 5.01)*
Hypertensive heart disease				
Women	0.74 (-0.79, 2.30)	2.47 (0.46, 4.52)*	1.19 (0.70, 1.69) *	4.57 (3.90, 5.24)*
Men	2.87 (-0.40, 6.24)	3.20 (1.41, 5.01)*	3.09 (2.64, 3.55) *	5.27 (3.97, 6.59)*
Stroke				
Women	-3.18 (-4.17, -2.19)*	0.76 (-0.01, 1.53)	-3.91 (-4.74, -3.07) *	-0.10 (-0.63, 0.44)
Men	-3.95 (-4.18, -3.72)*	0.92 (0.27, 1.58)*	-4.33 (-5.01, -3.65) *	-0.05 (-0.32, 0.21)
Other CVD				
Women	-0.89 (-1.38, -0.40)*	-0.31 (-0.61, -0.02)*	-0.68 (-1.08, -0.27) *	0.28 (-1.70, 2.29)
Men	-1.40 (-1.68, -1.12)*	-0.42 (-3.56, 2.81)	-0.84 (-1.17, -0.50) *	0.44 (0.18, 0.69) *

* indicates that the average annual percent change is significantly different from zero (P<0.05).

CVD = cardiovascular disease.

Table S4. Average annual percent change in age-adjusted mortality rates in Hispanic and Non-HispanicWhite adults attributed to cardiovascular diseases stratified by urbanicity.

		Average annual per	cent change (95% CI)	
	Hispani	c adults	Non-Hispanic	: White adults
Cardiovascular disease subtype	(1999 – 2011)	(2011 – 2018)	(1999 – 2011)	(2011 – 2018)
Total CVD				
Large metro	-3.80 (-4.34, -3.26)*	-1.00 (-1.36, -0.64)*	-3.72 (-4.13, -3.30) *	-0.71 (-1.00, -0.42) *
Medium-small metro	-3.40 (-3.82, -2.98)*	-1.02 (-1.39, -0.66)*	-3.42 (-3.75, -3.09) *	-0.43 (-0.61, -0.24) *
Rural	-4.19 (-4.52, -3.85)*	-0.94 (-1.62, -0.26)*	-2.98 (-3.53, -2.43) *	-0.43 (-0.73, -0.12) *
Ischemic heart disease				
Large metro	-5.35 (-5.81, -4.88)*	-3.40 (-3.97, -2.83)*	-4.95 (-5.23, -4.68) *	-2.82 (-3.30, -2.34)*
Medium-small metro	-4.65 (-6.42, -2.84)*	-2.21 (-2.97, -1.44)*	-4.36 (-4.80, -3.93) *	-2.36 (-2.62, -2.10) *
Rural	-5.41 (-5.78, -5.05)*	-1.99 (-2.73, -1.25)	-3.86 (-4.25, -3.48) *	-1.75 (-1.96, -1.55)*
Heart failure				
Large metro	0.19 (-0.13, 0.52)	3.48 (2.57, 4.41)*	-0.68 (-2.06, 0.72)	3.97 (3.35, 4.59)*
Medium-small metro	-1.60 (-2.56, -0.63)*	1.12 (-6.26, 9.08)	-1.81 (-2.51, -1.10) *	3.30 (2.52, 4.08)*
Rural	-3.26 (-8.80, 2.62)	1.72 (-0.16, 3.64)	-2.09 (-2.56, -1.62) *	1.84 (0.49, 3.20) *
Hypertensive heart disease				
Large metro	1.36 (0.44, 3.19) *	3.02 (1.22, 4.85)*	2.22 (1.59, 2.84) *	3.31 (2.33, 4.30) *
Medium-small metro	0.91 (0.34, 1.48)*	0.91 (0.34, 1.48)*	1.25 (0.82, 1.69) *	5.59 (4.39, 6.81) *
Rural	1.39 (0.34, 2.46)*	1.39 (0.34, 2.46)*	2.46 (2.11, 2.81) *	6.89 (5.28, 8.52)*
Stroke				
Large metro	-3.66 (-4.09, -3.22)*	1.70 (0.49, 2.91)*	-4.34 (-5.58, -3.08) *	0.68 (0.11, 1.26)*
Medium-small metro	-3.58 (-4.05, -3.12)*	-1.00 (-2.13, 0.14)	-4.08 (-4.74, -3.42) *	-0.28 (-0.69, 0.13)*
Rural	-4.47 (-6.17, -2.73)*	-1.67 (-2.44, -0.88)*	-3.52 (-3.93, -3.10) *	-1.27 (-1.51, -1.03)*
Other CVD				
Large metro	-0.65 (-0.92, -0.37)*	-0.85 (-1.96, 0.27)	-0.73 (-1.06, -0.40) *	0.14 (-1.75, 2.07)
Medium-small metro	-1.14 (-3.58, 1.37)	-0.72 (-1.03, -0.41)*	-0.79 (-1.18, -0.39) *	0.41 (0.10, 0.71) *
Rural	-1.91 (-3.34, -0.46)*	0.64 (0.12, 1.16)*	-0.43 (-0.88, 0.02)	0.70 (0.33, 1.06)*

* indicates that the average annual percent change is significantly different from zero (P<0.05). CVD = cardiovascular disease.